Cutter Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cutter Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-273,533	Closed	-$22.5M	–	31
2024 Q2	$22.5M	Buy	273,533 +98,533	+56%	+$8.2M	6.8%	1
2024 Q1	$15.3M	Buy	175,000 +45,094	+35%	+$4.04M	5.84%	5
2023 Q4	$12.5M	Buy	+129,906	New	+$11.5M	5.99%	5

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Cutter Capital Management's BMRN Position: Q3 2024 in Review

Cutter Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 273,533 shares — an estimated $22.5M sold.

Cutter Capital Management first reported a position in BMRN in Q4 2023 and held it in 3 quarters. The position peaked at $22.5M in Q2 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Cutter Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Cutter Capital Management sold 273,533 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $22.5M.
Cutter Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 3 quarters.
Cutter Capital Management's BioMarin Pharmaceuticals position peaked at $22.5M in Q2 2024.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Cutter Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.